Quality-of-life analysis of pembrolizumab vs brentuximab vedotin for relapsed/refractory classical Hodgkin lymphoma

Pembrolizumab versus brentuximab vedotin in relapsed or refractory classical Hodgkin lymphoma (KEYNOTE-204): an interim analysis of a multicentre, randomised, open-label, phase 3 study

(2021) John Kuruvilla et al.   LANCET ONCOLOGY

Optimizing outcomes in relapsed/refractory Hodgkin lymphoma: a review of current and forthcoming therapeutic strategies

(2020) Theodoros P. Vassilakopoulos et al.   Therapeutic Advances in Hematology

Health-related quality of life (QoL) in patients with advanced melanoma receiving immunotherapies in real-world clinical practice settings

(2020) Richard W. Joseph et al.   QUALITY OF LIFE RESEARCH

Investigating Potential Bias in Patient-Reported Outcomes in Open-label Cancer Trials

(2019) Jessica K. Roydhouse et al.   JAMA Oncology

Nivolumab for the treatment of relapsed and refractory classical Hodgkin lymphoma after ASCT and in ASCT-naïve patients

(2019) Kirill V. Lepik et al.   LEUKEMIA & LYMPHOMA

Health-Related Quality of Life in KEYNOTE-010: a Phase II/III Study of Pembrolizumab Versus Docetaxel in Patients With Previously Treated Advanced, Programmed Death Ligand 1–Expressing NSCLC

(2019) Fabrice Barlesi et al.   Journal of Thoracic Oncology

Patient-reported outcomes in KEYNOTE-087, a phase 2 study of pembrolizumab in patients with classical Hodgkin lymphoma

(2019) Bastian von Tresckow et al.   LEUKEMIA & LYMPHOMA

Pembrolizumab in relapsed or refractory Hodgkin lymphoma: 2-year follow-up of KEYNOTE-087

(2019) Robert Chen et al.   BLOOD

Health-Related Quality-of-Life Analysis From KEYNOTE-045: A Phase III Study of Pembrolizumab Versus Chemotherapy for Previously Treated Advanced Urothelial Cancer

(2018) David J. Vaughn et al.   JOURNAL OF CLINICAL ONCOLOGY

Nivolumab for Relapsed/Refractory Classic Hodgkin Lymphoma After Failure of Autologous Hematopoietic Cell Transplantation: Extended Follow-Up of the Multicohort Single-Arm Phase II CheckMate 205 Trial

(2018) Philippe Armand et al.   JOURNAL OF CLINICAL ONCOLOGY

Five-year PFS from the AETHERA trial of brentuximab vedotin for Hodgkin lymphoma at high risk of progression or relapse

(2018) Craig H. Moskowitz et al.   BLOOD

Trustworthiness of Patient-Reported Outcomes in Unblinded Cancer Clinical Trials

(2017) Thomas M. Atkinson et al.   JAMA Oncology

Quality of life results from a phase 3 study of brentuximab vedotin consolidation following autologous haematopoietic stem cell transplant for persons with Hodgkin lymphoma

(2016) Scott D. Ramsey et al.   BRITISH JOURNAL OF HAEMATOLOGY

Health-related quality of life in the randomised KEYNOTE-002 study of pembrolizumab versus chemotherapy in patients with ipilimumab-refractory melanoma

(2016) Dirk Schadendorf et al.   EUROPEAN JOURNAL OF CANCER

Health-related quality of life in Hodgkin lymphoma: a systematic review

(2016) Nadine Linendoll et al.   Health and Quality of Life Outcomes

PD-L1 and PD-L2 Genetic Alterations Define Classical Hodgkin Lymphoma and Predict Outcome

(2016) Margaretha G.M. Roemer et al.   JOURNAL OF CLINICAL ONCOLOGY

Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial

(2016) Anas Younes et al.   LANCET ONCOLOGY

Constitutive AP-1 Activity and EBV Infection Induce PD-L1 in Hodgkin Lymphomas and Posttransplant Lymphoproliferative Disorders: Implications for Targeted Therapy

(2012) M. R. Green et al.   CLINICAL CANCER RESEARCH

Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin's lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trial

(2012) Andreas Engert et al.   LANCET

Second-line salvage chemotherapy for transplant-eligible patients with Hodgkin's lymphoma resistant to platinum-containing first-line salvage chemotherapy

(2011) D. Villa et al.   HAEMATOLOGICA

Evidence-Based Guidelines for Determination of Sample Size and Interpretation of the European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30

(2010) Kim Cocks et al.   JOURNAL OF CLINICAL ONCOLOGY

Long-Term Effects of High-Dose Chemotherapy and Radiation for Relapsed and Refractory Hodgkin's Lymphoma

(2008) Karyn A. Goodman et al.   JOURNAL OF CLINICAL ONCOLOGY